Perioperative blood glucose management, neutrophil function, and surgical site infection risk — Page 1998
Neutrophils are the first responders against bacterial contamination at a surgical site. Their effectiveness depends on a coordinated sequence — sensing chemical gradients, migrating toward the site, engulfing bacteria, and killing them with reactive oxygen species. Elevated glucose interferes with essentially every step of this sequence, while simultaneously creating a more hospitable environment for bacterial replication.
Neutrophil antibacterial function is a multi-step cascade, and hyperglycemia degrades performance at nearly every stage:
• Chemotaxis: neutrophils normally follow chemokine gradients (IL-8, complement fragments) toward a contaminated wound. High extracellular glucose blunts directional sensing and slows migration velocity, delaying arrival at the site of bacterial entry.
• Adhesion and margination: glucose-driven changes in endothelial adhesion molecule expression can reduce the efficiency with which circulating neutrophils marginate and exit into tissue.
• Phagocytosis: engulfment of opsonized bacteria requires active cytoskeletal remodeling and Fc-receptor signaling — both measurably reduced in hyperglycemic conditions in laboratory and clinical studies.
• Oxidative (respiratory) burst: the NADPH-oxidase-driven production of reactive oxygen species that kills engulfed bacteria is blunted when ambient glucose is elevated, allowing a larger fraction of phagocytosed organisms to survive intracellularly.
• Net effect: a surgical wound bathed in elevated glucose faces a weakened first line of cellular defense precisely when bacterial contamination is most likely — at the time of incision and closure.
This impairment is not limited to patients with diagnosed diabetes. Surgical and anesthetic stress trigger a catecholamine- and cortisol-driven counter-regulatory response that can produce transient "stress hyperglycemia" even in patients with no prior history of diabetes — meaning glycemic vigilance is relevant to essentially all major surgical patients.
Beyond disabling host defenses, elevated local and systemic glucose changes the wound microenvironment in ways that favor bacterial proliferation:
• Nutrient availability: many common surgical-site pathogens (Staphylococcus aureus among them) grow more readily in glucose-rich extracellular fluid, effectively feeding the organisms host defenses are trying to clear.
• Microvascular effects: chronic and acute hyperglycemia can impair microvascular perfusion and endothelial function, reducing oxygen and nutrient delivery to healing tissue and blunting antibiotic penetration to the wound bed.
• Collagen synthesis and wound healing: hyperglycemia interferes with fibroblast function and collagen cross-linking, slowing the mechanical closure of the wound and prolonging the window during which bacteria can establish infection.
• Advanced glycation end-products (AGEs): sustained elevated glucose promotes AGE formation, which can further impair leukocyte function and tissue repair through receptor-mediated inflammatory signaling.
Taken together, hyperglycemia produces a double insult: an impaired cellular defense responding to an environment that has been simultaneously made more favorable for the pathogen.
Early enthusiasm for very tight intraoperative glucose control gave way, after large randomized trials, to more moderate targets. The reason is straightforward: aggressive tight control substantially raises the risk of iatrogenic hypoglycemia, and hypoglycemic episodes carry their own serious morbidity — including neurologic injury and cardiovascular stress — that can offset the benefits of avoiding hyperglycemia.
In the early 2000s, single-center studies of intensive insulin therapy targeting near-normal glucose (roughly 80–110 mg/dL) in critically ill and surgical patients reported striking reductions in mortality and infection. This led to widespread adoption of very tight glycemic targets in ICUs and operating rooms.
Subsequent larger, multi-center randomized trials told a more complicated story: intensive control did reduce some complications in certain populations, but it also produced a marked increase in severe hypoglycemic events — and in some trials, tight control was associated with higher mortality overall, largely attributable to hypoglycemia-related harm.
The field response was a recalibration: rather than chasing near-normal glucose, most current perioperative and critical-care guidelines recommend a moderate target band — commonly cited around 140–180 mg/dL — that meaningfully reduces the harms of hyperglycemia while keeping the risk of hypoglycemia low.
Hypoglycemia during and after surgery is not a benign side effect of aggressive glucose lowering — it is an independent source of harm:
• Neurologic risk: the brain depends on a continuous glucose supply; significant or prolonged hypoglycemia can cause confusion, seizures, and, in severe cases, permanent neurologic injury, and it is often harder to recognize under anesthesia or sedation because classic symptoms (tremor, diaphoresis, palpitations) are masked.
• Cardiovascular stress: hypoglycemia triggers a sympathoadrenal counter-regulatory surge that can provoke arrhythmias and myocardial ischemia, a particular concern in patients with existing cardiovascular disease undergoing surgery.
• Detection delay under anesthesia: general anesthesia blunts the patient-reported warning signs of low glucose, meaning hypoglycemia may only be caught by scheduled point-of-care testing — reinforcing why moderate targets with reasonable safety margins are preferred over targets that leave little room for error.
The practical implication: perioperative glucose management aims for a band that is "good enough" to blunt the infection- and healing-related harms of hyperglycemia, while deliberately leaving a safety margin above the hypoglycemic threshold.
The shift from tight to moderate glycemic targets is one of the clearer examples in perioperative medicine of a therapy being right-sized after evidence showed the aggressive version caused more harm than the moderate version — precision was not the same as safety.
For elective surgery, the perioperative period is not the only — or even the best — window to influence glycemic-related risk. Preoperative assessment of long-term glucose control via HbA1c, followed by a period of optimization when feasible, gives clinicians a chance to reduce baseline risk before a patient ever reaches the operating room.
HbA1c (glycated hemoglobin) reflects average blood glucose exposure over the preceding roughly two to three months — it does not capture minute-to-minute variability, but it is an excellent marker of chronic glycemic burden.
Patients with poorly controlled diabetes (elevated HbA1c) enter surgery already carrying impaired microvascular function, blunted immune cell performance, and often subclinical tissue changes accumulated over months. These patients tend to have a higher baseline risk of surgical site infection and delayed wound healing independent of what their glucose happens to read on the morning of surgery.
For elective procedures — particularly those with implants, prosthetic material, or extensive tissue dissection where infection consequences are severe — preoperative HbA1c assessment allows risk stratification and, where clinically appropriate, a deliberate window to improve control before proceeding.
When surgery can be safely deferred, optimization strategies may include:
• Medication review and intensification: adjusting oral hypoglycemic agents or insulin regimens in coordination with the patient's diabetes care team.
• Structured follow-up: repeat HbA1c and home glucose monitoring to confirm improving trends before rescheduling surgery.
• Patient education: reinforcing self-monitoring, diet, and medication adherence in the weeks leading up to the procedure.
• Multidisciplinary coordination: for patients with long-standing poor control, involving endocrinology or a perioperative medicine service to balance the benefits of optimization against the risks of delaying a needed operation.
This is a balancing act, not a rigid rule: for urgent or emergent surgery, or when a modest degree of preoperative hyperglycemia cannot be substantially improved in a clinically reasonable window, the operation proceeds with heightened perioperative glycemic vigilance instead. But whenever elective timing allows it, addressing chronic control before surgery is a meaningfully different lever than reacting to glucose readings during the case itself.
Preoperative optimization and intraoperative/postoperative monitoring are complementary, not substitutes for one another — a well-controlled HbA1c going into surgery does not eliminate the need for perioperative glucose checks, since acute stress hyperglycemia can still occur regardless of baseline control.
Glycemic risk does not switch off once surgery begins, nor does it end when the patient leaves the operating room. Regular point-of-care glucose monitoring spanning the preoperative, intraoperative, and postoperative periods — paired with a standardized insulin correction protocol — is how moderate glycemic targets are actually maintained in practice.
Not every patient needs the same monitoring intensity. Risk-based monitoring generally scales up for:
• Longer procedures: extended anesthetic and surgical stress produces a larger, more sustained counter-regulatory hormone response, increasing the chance of clinically significant hyperglycemia developing over the course of the case.
• Known diabetic patients: both type 1 and type 2 diabetics have less physiologic reserve to buffer glycemic swings and are more likely to need active insulin correction during surgery.
• Cardiac and other major/complex surgery: procedures with foreign material (grafts, prosthetics, hardware) or major tissue disruption carry higher infection stakes, making tight monitoring more clinically valuable.
For short, low-risk procedures in non-diabetic patients, monitoring may be limited to a single baseline check, whereas a multi-hour cardiac case in a known diabetic patient may involve glucose checks roughly every one to two hours throughout surgery and into recovery.
A monitoring value is only useful if it is tied to a predefined response. Standard perioperative insulin correction protocols typically define:
• A target band (commonly ~140–180 mg/dL) above which correction is triggered.
• A stepwise or weight-based insulin dosing scale, often via intravenous insulin infusion intraoperatively for tighter titration, transitioning to subcutaneous correction doses postoperatively.
• A recheck interval after any correction dose, to confirm the glucose is trending back into range without overcorrecting into hypoglycemia.
• A parallel hypoglycemia protocol (dextrose administration, reduced/held insulin) for any reading below the hypoglycemic threshold, since correction errors can push a patient below target as easily as above it.
This closed loop — check, compare to target, correct if needed, recheck — is what allows glycemic targets defined on paper to actually be achieved at the bedside across a multi-hour, multi-phase perioperative course.
Postoperative monitoring commonly continues for at least the first 24–48 hours after major surgery, since stress hyperglycemia driven by surgical inflammation and catecholamine release can persist well after the incision has closed — a window highly relevant to surgical site infection risk.
The clinical rationale for perioperative glycemic control is ultimately anchored in outcomes data: sustained postoperative hyperglycemia is consistently associated with meaningfully higher rates of surgical site infection, especially after cardiac surgery, where the association has been studied most extensively. This is why glycemic management is embedded as a standard component of SSI prevention bundles rather than treated as a separate, optional consideration.
Across multiple surgical outcomes studies, the relationship between postoperative glucose and surgical site infection risk behaves in a dose-dependent way rather than as a sharp on/off threshold:
• Higher peak postoperative glucose values are associated with progressively higher SSI rates.
• Longer duration of sustained hyperglycemia compounds the risk beyond any single elevated reading — a brief spike is generally less concerning than glucose that remains elevated for many hours.
• The relationship holds across both patients with pre-existing diabetes and those experiencing purely stress-induced hyperglycemia, reinforcing that glucose level itself — not diabetes status — is the operative risk driver in the immediate postoperative window.
This dose-response pattern is exactly why perioperative protocols focus on maintaining glucose within a target band throughout the case and recovery, rather than only reacting to a single alarming number.
Cardiac surgery — particularly coronary artery bypass grafting — has produced some of the clearest evidence linking postoperative hyperglycemia to deep and superficial sternal wound infection. Sternotomy wounds are a demanding test case: they involve bone, extensive tissue planes, and in some cases prosthetic or graft material, making infection consequences severe and infection prevention correspondingly high-value to study rigorously.
Studies in this population found that structured postoperative glucose management protocols reduced deep sternal wound infection rates compared to historical practice without such protocols — evidence influential enough that glycemic control became a standard, guideline-endorsed component of cardiac surgical care.
The underlying mechanism — impaired neutrophil function and a bacteria-favorable wound environment — is not specific to cardiac surgery. It generalizes to major surgery broadly, which is why glycemic management appears alongside prophylactic antibiotic timing, maintenance of normothermia, and appropriate hair removal technique as a standard element of comprehensive surgical site infection prevention bundles.
Glycemic management earns its place in SSI prevention bundles not because glucose control is a cardiac-specific concern, but because the underlying biology — impaired neutrophil function and a bacteria-favorable wound milieu under hyperglycemia — applies to essentially any major operation, in diabetic and non-diabetic patients alike.